Genotyping HLA alleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art

References

• Oshikoya KA, Ogunyinka IA, Ogar CK, et al. Severe cutaneous adverse drug reactions manifesting as Stevens-Johnson syndrome and toxic epidermal necrolysis reported to the national pharmacovigilance center in Nigeria: a database review from 2004 to 2017. Ther Adv Drug Saf. 2020;11:2042098620905998.
   Web of Science ®Google Scholar
• Marzano AV, Borghi A, Cugno M. Adverse drug reactions and organ damage: the skin. Eur J Intern Med. 2016;28:17–24.
   PubMed Web of Science ®Google Scholar
• Chang CJ, Chen C-B, Hung S-I, et al. Pharmacogenetic testing for prevention of severe cutaneous adverse drug reactions. Front Pharmacol. 2020;11:969.
   PubMed Web of Science ®Google Scholar
• Ramirez E, Bellón T, Tong HY, et al. Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacol Res. 2017;115:168–178.
   PubMed Web of Science ®Google Scholar
• Phillips EJ, Chung W-H, Mockenhaupt M, et al. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol. 2011;127(3 Suppl):S60–6.
   PubMed Web of Science ®Google Scholar
• Karnes JH, Miller MA, White KD, et al. Applications of immunopharmacogenomics: predicting, preventing, and understanding immune-mediated adverse drug reactions. Annu Rev Pharmacol Toxicol. 2019;59(1):463–486.
   PubMedGoogle Scholar
• Uetrecht J. Immune-mediated adverse drug reactions. Chem Res Toxicol. 2009;22(1):24–34.
   PubMed Web of Science ®Google Scholar
• Mustafa SS, Ostrov D, Yerly D. Severe Cutaneous adverse drug reactions: presentation, risk factors, and management. Curr Allergy Asthma Rep. 2018;18(4):26.
   PubMed Web of Science ®Google Scholar
• Hoetzenecker W, Nägeli M, Mehra ET, et al. Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol. 2016;38(1):75–86.
   PubMed Web of Science ®Google Scholar
• Feldmeyer L, Heidemeyer K, Yawalkar N. Acute generalized Exanthematous Pustulosis: pathogenesis, genetic background, clinical variants and therapy. Int J Mol Sci. 2016;17(8):1214.
   Web of Science ®Google Scholar
• Duong TA, Valeyrie-Allanore L, Wolkenstein P, et al. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390(10106):1996–2011.
   PubMed Web of Science ®Google Scholar
• Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, et al. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018;54(1):147–176.
   PubMed Web of Science ®Google Scholar
• Orime M. Immunohistopathological findings of severe cutaneous adverse drug reactions. J Immunol Res. 2017;2017:6928363.
   PubMed Web of Science ®Google Scholar
• Jung JW, Kim J-Y, Park I-W, et al. Genetic markers of severe cutaneous adverse reactions. Korean J Intern Med. 2018;33(5):867–875.
   PubMed Web of Science ®Google Scholar
• *Chung WH, Chang W-C, Lee Y-S, et al., Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA. 312(5): 525–534. 2014.
   PubMed Web of Science ®Google Scholar
• Fan WL, Shiao M-S, Hui RC-Y, et al. HLA association with Drug-Induced adverse reactions. J Immunol Res. 2017;2017:3186328.
   PubMed Web of Science ®Google Scholar
• Sousa-Pinto B, Pinto-Ramos J, Correia C, et al. Pharmacogenetics of abacavir hypersensitivity: a systematic review and meta-analysis of the association with HLA-B*57:01. J Allergy Clin Immunol. 2015;136(4):1092–4 e3.
   PubMed Web of Science ®Google Scholar
• Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727–732.
   PubMed Web of Science ®Google Scholar
• Martin MA, Hoffman JM, Freimuth RR, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B Genotype and Abacavir dosing: 2014 update. Clin Pharmacol Ther. 2014;95(5):499–500.
   PubMed Web of Science ®Google Scholar
• Manson LEN, Swen JJ, Guchelaar HJ. Diagnostic test criteria for HLA genotyping to prevent drug hypersensitivity reactions: a systematic review of actionable HLA recommendations in CPIC and DPWG guidelines. Front Pharmacol. 2020;11:567048.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhou J-Q, Zhou L-M, et al. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure. 2011;20(6):446–448.
   PubMed Web of Science ®Google Scholar
• Shi YW, Min F-L, Qin B, et al. Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502? Basic Clin Pharmacol Toxicol. 2012;111(1):58–64.
   PubMed Web of Science ®Google Scholar
• *Sukasem C, Chaichan C, Nakkrut T, et al. Association between HLA-B alleles and carbamazepine-induced maculopapular exanthema and severe cutaneous reactions in Thai patients. J Immunol Res. 2018;2018:2780272.
   PubMed Web of Science ®Google Scholar
• *Chung WH, Hung S-I, Hong H-S, et al., Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 428(6982): 486. 2004.
   PubMedGoogle Scholar
• Lim KS, Kwan P, Tan CT. Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review. Neurol Asia. 2008;13:15–21.
   Web of Science ®Google Scholar
• Mehta TY, Prajapati L, Mittal B, et al. Association of HLA-BFNx011502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol. 2009;75(6):579–582.
   PubMed Web of Science ®Google Scholar
• Nguyen DV, Chu HC, Nguyen DV, et al. HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. Asia Pac Allergy. 2015;5(2):68–77.
   PubMed Web of Science ®Google Scholar
• Amstutz U, Shear NH, Rieder MJ, et al. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia. 2014;55(4):496–506.
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M, Wang C-W, Hung S-I, et al. HLA-B*57:01 confers genetic susceptibility to carbamazepine-induced SJS/TEN in Europeans. Allergy. 2019;74(11):2227–2230.
   PubMed Web of Science ®Google Scholar
• Wang Q, Sun S, Xie M, et al. Association between the HLA-B alleles and carbamazepine-induced SJS/TEN: a meta-analysis. Epilepsy Res. 2017;135:19–28.
   PubMed Web of Science ®Google Scholar
• Dean L. Carbamazepine therapy and HLA genotype, in medical genetics summaries. Pratt VM., Scott SA., Pirmohamed M., et al., Editors. Bethesda (MD): National Center for Biotechnology Information (US); 2012.
   Google Scholar
• Cheung YK, Cheng S-H, Chan EJM, et al. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013;54(7):1307–1314.
   PubMed Web of Science ®Google Scholar
• Hung SI, Chung W-H, Liu Z-S, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics. 2010;11(3):349–356.
   PubMed Web of Science ®Google Scholar
• Manuyakorn W, Likkasittipan P, Wattanapokayakit S, et al. Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children. Epilepsy Res. 2020;162:106321.
   PubMed Web of Science ®Google Scholar
• Chang CC, Ng -C-C, Too C-L, et al. Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population. Pharmacogenomics J. 2017;17(2):170–173.
   PubMed Web of Science ®Google Scholar
• Hung SI, Chung W-H, Liou L-B, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134–4139.
   PubMed Web of Science ®Google Scholar
• *Sukasem C., Jantararoungtong T., Kuntawong P., et al. HLA-B*58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: implication for Clinical Interpretation in Thailand. Front Pharmacol. 2016;7:186.
   PubMed Web of Science ®Google Scholar
• Kaniwa N., Saito Y., Aihara M., et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008;9(11):1617–1622.
   PubMed Web of Science ®Google Scholar
• Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheumatol. 2016;12(4):235–242.
   PubMed Web of Science ®Google Scholar
• Kang HR, Jee YK, Kim Y-S, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics. 2011;21(5):303–307.
   PubMed Web of Science ®Google Scholar
• Li X, Zhao Z, Sun SS. Association of human leukocyte antigen variants and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis. Am J Health Syst Pharm. 2017;74(9):e183–e192.
   PubMed Web of Science ®Google Scholar
• Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013;93(2):153–158.
   PubMed Web of Science ®Google Scholar
• Tangamornsuksan W, Lohitnavy M. Association Between HLA-B*1301 and Dapsone-Induced Cutaneous adverse drug reactions: a systematic review and Meta-analysis. JAMA Dermatol. 2018;154(4):441–446.
   PubMed Web of Science ®Google Scholar
• Park HJ, Park J-W, Kim SH, et al. The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses. Expert Opin Drug Saf. 2020;19(10):1349–1356.
   PubMed Web of Science ®Google Scholar
• Zhang FR, Liu H, Irwanto A, et al. HLA-B*13:01 and the Dapsone hypersensitivity syndrome. N Engl J Med. 2013;369(17):1620–1628.
   PubMed Web of Science ®Google Scholar
• Tempark T, Satapornpong P, Rerknimitr P, et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population. Pharmacogenet Genomics. 2017;27(12):429–437.
   PubMed Web of Science ®Google Scholar
• Kongpan T, Mahasirimongkol S, Konyoung P, et al. Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. Pharmacogenet Genomics. 2015;25(8):402–411.
   PubMed Web of Science ®Google Scholar
• *Sukasem C, Pratoomwun J, Satapornpong P, et al., Genetic Association of Co-Trimoxazole-Induced Severe cutaneous adverse reactions is Phenotype-Specific: HLA Class I genotypes and haplotypes. Clin Pharmacol Ther. 108(5): 1078–1089. 2020.
   PubMed Web of Science ®Google Scholar
• Wang CW., Tassaneeyakul W., Chen CB., et al. Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians. J Allergy Clin Immunol. 2020;147 (4): 1402-1412.
   Web of Science ®Google Scholar
• De Luca JF, Holmes NE, Trubiano JA. Adverse reactions to vancomycin and cross-reactivity with other antibiotics. Curr Opin Allergy Clin Immunol. 2020;20(4):352–361.
   PubMed Web of Science ®Google Scholar
• Konvinse KC, Trubiano JA, Pavlos R, et al. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol. 2019;144(1):183–192.
   PubMed Web of Science ®Google Scholar
• Ueta M, Kaniwa N, Sotozono C, et al. Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement. Sci Rep. 2014;4(1):4862.
   PubMedGoogle Scholar
• Kim SH, Kim M, Lee KW, et al. HLA-B*5901 is strongly associated with methazolamide-induced Stevens–Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics. 2010;11(6):879–884.
   PubMed Web of Science ®Google Scholar
• Yang F, Xuan J, Chen J, et al. HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese. Pharmacogenomics J. 2016;16(1):83–87.
   PubMed Web of Science ®Google Scholar
• Carr DF, Chaponda M, Jorgensen AL, et al. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Clin Infect Dis. 2013;56(9):1330–1339.
   PubMed Web of Science ®Google Scholar
• Carr DF, Bourgeois S, Chaponda M, et al. Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population. J Antimicrob Chemother. 2017;72(4):1152–1162.
   PubMed Web of Science ®Google Scholar
• Dean L, Kane M. Phenytoin Therapy and HLA-B*15:02 and CYP2C9 genotypes, in medical genetics summaries. Pratt VM., Scott SA., Pirmohamed M., et al., Editors. Bethesda (MD): National Center for Biotechnology information (US); 2012
   Google Scholar
• Fohner AE, Rettie AE, Thai KK, et al. Associations of CYP2C9 and CYP2C19 Pharmacogenetic variation with phenytoin-Induced cutaneous adverse drug reactions. Clin Transl Sci. 2020;13(5):1004–1009.
   PubMed Web of Science ®Google Scholar
• Yampayon K, Sukasem C, Limwongse C, et al. Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions. Eur J Clin Pharmacol. 2017;73(7):855–865.
   PubMed Web of Science ®Google Scholar
• Suvichapanich S, Jittikoon J, Wichukchinda N, et al. Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children. J Hum Genet. 2015;60(8):413–417.
   PubMed Web of Science ®Google Scholar
• Sukasem C, Sririttha S, Tempark T, et al. Genetic and clinical risk factors associated with phenytoin-induced cutaneous adverse drug reactions in Thai population. Pharmacoepidemiol Drug Saf. 2020;29(5):565–574.
   PubMed Web of Science ®Google Scholar
• Su SC, Chen C-B, Chang W-C, et al. HLA Alleles and CYP 2C9*3 as predictors of phenytoin hypersensitivity in East Asians. Clin Pharmacol Ther. 2019;105(2):476–485.
   PubMed Web of Science ®Google Scholar
• Ciccacci C, Di Fusco D, Marazzi MC, et al. Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. Eur J Clin Pharmacol. 2013;69(11):1909–1916.
   PubMed Web of Science ®Google Scholar
• Zhao J, Hu L, Zhang L, et al. Causative drugs for drug-induced cutaneous reactions in central China: a 608-case analysis. An Bras Dermatol. 2019;94(6):664–670.
   PubMed Web of Science ®Google Scholar
• Gomes ESR, Marques ML, Regateiro FS. Epidemiology and risk factors for severe delayed drug hypersensitivity reactions. Curr Pharm Des. 2019;25(36):3799–3812.
   PubMed Web of Science ®Google Scholar
• Chen YC, Chiang -H-H, Cho Y-T, et al. Human herpes virus reactivations and dynamic cytokine profiles in patients with cutaneous adverse drug reactions --a prospective comparative study. Allergy. 2015;70(5):568–575.
   PubMed Web of Science ®Google Scholar
• Teraki Y, Murota H, Izaki S. Toxic epidermal necrolysis due to zonisamide associated with reactivation of human herpesvirus 6. Arch Dermatol. 2008;144(2):232–235.
   PubMedGoogle Scholar
• Ishida T, Kano Y, Mizukawa Y, et al. The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome. Allergy. 2014;69(6):798–805.
   PubMed Web of Science ®Google Scholar
• Yachoui R, Kolasinski SL, Feinstein DE. Mycoplasma pneumoniae with atypical stevens-johnson syndrome: a diagnostic challenge. Case Rep Infect Dis. 2013;2013:457161.
   PubMedGoogle Scholar
• Torres-Navarro I, de Unamuno-Bustos B, Botella-Estrada R. Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs). J Eur Acad Dermatol Venereol. 2021;35(3):607–614.
   PubMed Web of Science ®Google Scholar
• Plachouri KM, Vryzaki E, Georgiou S. Cutaneous adverse events of immune checkpoint inhibitors: a summarized overview. Curr Drug Saf. 2019;14(1):14–20.
   PubMed Web of Science ®Google Scholar
• Pavlos R, Mallal S, Ostrov D, et al. Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy. J Allergy Clin Immunol Pract. 2014;2(1):21–33.
   PubMed Web of Science ®Google Scholar
• Nguyen DV, Vidal C, Chu HC, et al. Human leukocyte antigen-associated severe cutaneous adverse drug reactions: from bedside to bench and beyond. Asia Pac Allergy. 2019;9(3):e20.
   PubMed Web of Science ®Google Scholar
• Yun J, Marcaida MJ, Eriksson KK, et al. Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01. J Immunol. 2014;192(7):2984–2993.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Galarza FF, McCabe A, Santos EJMD, et al. Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools. Nucleic Acids Res. 2020;48(D1):D783–D788.
   PubMed Web of Science ®Google Scholar
• Mendes D, Alves C, Loureiro M, et al. Drug-induced hypersensitivity: a 5-year retrospective study in a hospital electronic health records database. J Clin Pharm Ther. 2019;44(1):54–61.
   PubMed Web of Science ®Google Scholar
• Tang MM, Fok JS, Thong BY-H, et al. Diagnostic procedures & practices in drug allergy/hypersensitivity: a survey of 13 Asian countries. Asia Pac Allergy. 2020;10(4):e36.
   PubMed Web of Science ®Google Scholar
• Guo C, Xie X, Li J, et al. Pharmacogenomics guidelines: current status and future development. Clin Exp Pharmacol Physiol. 2019;46(8):689–693.
   PubMed Web of Science ®Google Scholar
• Phillips EJ, Sukasem C, Whirl‐Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of Carbamazepine and Oxcarbazepine: 2017 update. Clin Pharmacol Ther. 2018;103(4):574–581.
   PubMed Web of Science ®Google Scholar
• Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431–1446.
   PubMed Web of Science ®Google Scholar
• Sorich MJ, Wiese MD, Pekarsky B. Cost-effectiveness of genotyping to guide treatment. Pharmacogenomics. 2014;15(6):727–729.
   PubMed Web of Science ®Google Scholar
• Hoomans T, Severens JL. Economic evaluation of implementation strategies in health care. Implement Sci. 2014;9(1):168.
   PubMedGoogle Scholar
• Choi H, Mohit B. Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States. Epilepsia. 2019;60(7):1472–1481.
   PubMed Web of Science ®Google Scholar
• Rattanavipapong W, Koopitakkajorn T, Praditsitthikorn N, et al. Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Epilepsia. 2013;54(9):1628–1638.
   PubMed Web of Science ®Google Scholar
• Tiamkao S, Jitpimolmard J, Sawanyawisuth K, et al. Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand. Int J Clin Pharm. 2013;35(4):608–612.
   PubMed Web of Science ®Google Scholar
• Dong D, Sung C, Finkelstein EA. Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology. 2012;79(12):1259–1267.
   PubMed Web of Science ®Google Scholar
• Chong HY, Mohamed Z, Tan LL, et al. Is universal HLA-B*15:02 screening a cost-effective option in an ethnically diverse population? A case study of Malaysia. Br J Dermatol. 2017;177(4):1102–1112.
   PubMed Web of Science ®Google Scholar
• Plumpton CO, Yip VLM, Alfirevic A, et al. Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy. Epilepsia. 2015;56(4):556–563.
   PubMed Web of Science ®Google Scholar
• Jutkowitz E, Dubreuil M, Lu N, et al. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. Semin Arthritis Rheum. 2017;46(5):594–600.
   PubMed Web of Science ®Google Scholar
• Saokaew S, Tassaneeyakul W, Maenthaisong R, et al. Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population. PLoS One. 2014;9(4):e94294.
   PubMed Web of Science ®Google Scholar
• Chong HY, Lim YH, Prawjaeng J, et al. Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population. Pharmacogenet Genomics. 2018;28(2):56–67.
   PubMed Web of Science ®Google Scholar
• Kishore A, Petrek M. Next-Generation sequencing based HLA typing: deciphering immunogenetic aspects of Sarcoidosis. Front Genet. 2018;9:503.
   PubMed Web of Science ®Google Scholar
• Wei CY, Lee MT, Chen YT. Pharmacogenomics of adverse drug reactions: implementing personalized medicine. Hum Mol Genet. 2012;21(R1):R58–65.
   PubMed Web of Science ®Google Scholar
• Roden DM, Van Driest SL, Mosley JD, et al. Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome. Clin Pharmacol Ther. 2018;103(5):787–794.
   PubMed Web of Science ®Google Scholar
• Schildcrout JS, Denny JC, Roden DM. On the potential of preemptive genotyping towards preventing Medication-Related adverse events: results from the South Korean National Health Insurance Database. Drug Saf. 2017;40(1):1–2.
   PubMed Web of Science ®Google Scholar
• Su SC, Hung S-I, Fan W-L, et al. Severe cutaneous adverse reactions: the pharmacogenomics from research to clinical implementation. Int J Mol Sci. 2016;17(11):1890.
   Web of Science ®Google Scholar
• Dilokthornsakul P, Sawangjit R, Inprasong C, et al. Healthcare utilization and cost of Stevens-Johnson syndrome and toxic epidermal necrolysis management in Thailand. J Postgrad Med. 2016;62(2):109–114.
   PubMed Web of Science ®Google Scholar
• *Sukasem C, Chantratita W. A success story in pharmacogenomics: genetic ID card for SJS/TEN. Pharmacogenomics. 2016;17(5):455–458.
   PubMed Web of Science ®Google Scholar
• Satapornpong P, Jinda P, Jantararoungtong T, et al. Human Leukocyte Antigen Class I and Class II in Thai population: implication for clinical pharmacogenomics implementation. Front Pharmacol. 2020;11:78.
   PubMed Web of Science ®Google Scholar
• Kumar D. The genomic and precision medicine in clinical practice –Current perspectives and future directions. The Physician. 2020;6(3):1–10.
   Google Scholar
• Huser V, Sincan M, Cimino JJ. Developing genomic knowledge bases and databases to support clinical management: current perspectives. Pharmgenomics Pers Med. 2014;7:275–283.
   PubMedGoogle Scholar
• Keeling NJ, Rosenthal MM, West-Strum D, et al. Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers. Genet Med. 2019;21(5):1224–1232.
   PubMed Web of Science ®Google Scholar
• Ngorsuraches S, Meng W, Kim B-Y, et al. Drug reimbursement decision-making in Thailand, China, and South Korea. Value Health. 2012;15(1 Suppl):S120–5.
   PubMed Web of Science ®Google Scholar
• Sung C, Tan L, Limenta M, et al. Usage pattern of Carbamazepine and Associated Severe Cutaneous Adverse Reactions in Singapore following implementation of HLA-B*15:02 genotyping as standard-of-Care. Front Pharmacol. 2020;11:527.
   PubMed Web of Science ®Google Scholar
• Thong BY. Stevens-Johnson syndrome/toxic epidermal necrolysis: an Asia-Pacific perspective. Asia Pac Allergy. 2013;3(4):215–223.
   PubMedGoogle Scholar
• Dean L, Kane M. Allopurinol Therapy and HLA-B*58:01 genotype. In: Pratt VM, Scott SA, Pirmohamed M., et al. editors. Medical Genetics Summaries. Bethesda (MD): National Center for Biotechnology Information (US); 2012.
   Google Scholar
• Satapornpong P, Pratoomwun J, Rerknimitr P, et al. HLA-B*13:01 is a predictive marker of Dapsone-Induced severe cutaneous adverse reactions in Thai patients. Front Immunol. 2021;12:661135.
   PubMed Web of Science ®Google Scholar
• Pratoomwun J, Thomson P, Jaruthamsophon K. Characterization of T-Cell responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity patients expressing HLA-B*13:01. Front Immunol. 2021;12:658593.
   PubMed Web of Science ®Google Scholar
• Sukasem C, Jantararoungtong T, Koomdee N, et al. Pharmacogenomics research and its clinical implementation in Thailand: lessons learned from the resource-limited settings. Drug Metab Pharmacokinet. 2021;39:100399.
   PubMed Web of Science ®Google Scholar
• Puangpetch A, Koomdee N, Chamnanphol M, et al. HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity. Front Genet. 2015;5:478.
   PubMed Web of Science ®Google Scholar